Trial Profile

IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System

Status: Suspended

Phase of Trial: Phase I

Latest Information Update: 10 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ridaforolimus (Primary)
Indications Coronary artery restenosis
Focus Adverse reactions; Therapeutic Use
Acronyms IonMAN II
Sponsors Medinol

Most Recent Events

22 Sep 2025 Planned End Date changed from 1 Oct 2031 to 10 Aug 2026.
22 Sep 2025 Actual primary completion date changed to 7 Aug 2025.
22 Sep 2025 Status changed from not yet recruiting to suspended.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com